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between the two groups (p¼0.59). One-year TLR free rate was 95.7 
2.1% in the small BRS group and 92.5  2.1% in the large BRS group.
There were no differences between groups with regards to deﬁnite
stent thrombosis with was 1 late thrombosis in the small BRS group
and 1 acute thrombosis in the large BRS group.
CONCLUSIONS Percutaneous coronary intervention using small BRS
was associated with comparable outcomes when compared to larger
BRS with no observed increase in adverse events.
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BACKGROUND This in-vivo study sought to provide insights
regarding the feasibility and safety of performing complex bifurcation
techniques with the Absorb everolimus-eluting bioresorbable vascular
scaffold (BVS, Abbott Vascular, Santa Clara, US).
METHODS Twenty Adult New Zeeland white rabbits were anaes-
thetized and a long 6 Fr arterial sheath was placed in the carotid artery
extending to the distal aorta. Heparin was administered. Bifurcation
stenting procedures of the aorta-iliac bifurcation (70 angle) were
performed with 3.0x28 mm BVS using the following techniques: main-
vessel (MV) stenting with ballooning of side branch (SB) through the
BVS struts (Provisional stenting, n¼5), T-and protrusion (TAP, n¼5),
modiﬁed T (n¼5) and culotte (n¼5) stenting. Proximal optimization
technique with 3.5 mm non-compliant (NC) balloons at 16 atm and
mini-kissing balloon post-dilatation with 3.0 NC balloons at 5 atm
were performed in all procedures. Angiography, optical coherence
tomography (OCT) and post-procedural micro-computed tomography
(micro-CT) were performed.
RESULTS In all procedures angiographic results were excellent with
no evidence of dissection or SB compromise. Re-crossing through BVS
struts with guidewires and balloons þ/- second BVS (TAP þ culotte
procedures) was smooth. Provisional stenting optimally opened the
SB ostium without deforming the BVS. On OCT there was no malap-
position and micro-CT revealed good SB aperture and a single
connector fracture was present in the MV in 1 of the 5 cases. Modiﬁed
T stenting (SB stented ﬁrst, n¼5) and TAP stenting (MV stented ﬁrst,
n¼5) resulted in complete coverage of the SB ostium and carina. In
both techniques no signiﬁcant malapposition was present. On Micro-
CT, no strut fractures were present following modiﬁed T stenting,
whilst in 3 out of 5 TAP procedures single strut fractures were noted,
these did not cause luminal compromise. Culotte stenting (n¼5)
resulted in complete coverage of the bifurcation with an extensive
proximal segment of double-layered scaffold struts. In 3 of the 5
culotte procedures, OCT revealed signiﬁcant circumferential malap-
position at the level of the bifurcation. On micro-CT there was
distortion of MV and SB scaffolds at the level of the bifurcation with
single strut fractures present in all 5 cases. These fractures did not
cause luminal compromise.
CONCLUSIONS In this non-diseased in-vivo aorta-iliac bifurcation
model, it was feasible to perform complex bifurcation stenting using
Absorb BVS with excellent angiographic results. Provisional stenting
with additional TAP stenting seems a reasonable standard approach
for most bifurcation lesions. When a 2-stent technique is planned
from the outset, modiﬁed T-stenting was the most promising with no
evidence of signiﬁcant malapposition or scaffold disruption on OCT
and micro-CT, respectively. Finally, culotte stenting frequently
caused signiﬁcant circumferential malapposition, scaffold distortion
and strut fractures, the clinical impact of which is unknown.
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BACKGROUND Multiple studies have proven safety and feasibility of
the BVS bioresorbable scaffold. However, most of these studies were
restricted by rather non-complex lesions or short follow-up.
METHODS This is an investigator initiated, prospective, mono-center,
single-arm study. Inclusion criteria were patients presenting with
NSTEMI, stable, unstable angina, or silent ischemia caused by a de
novo stenotic lesion in a native previous untreated coronary artery.
Lesions with a Dmax (proximal and distal mean lumen diameter)
within the upper limit of 3.8 mm and the lower limit of 2.0 mm by
online QCA were obligatory. Exclusion criteria were patients with a
history of CABG, presentation with cardiogenic shock, bifurcation le-
sions requiring kissing balloon post-dilatation, STEMI patients
requiring immediate stent implantation, allergies or contra-in-
dications to antiplatelet therapy, female patient with child bearing
potential not taking adequate contraceptives or currently breast-
feeding, expected survival of less than one year. Procedural outcomes
and clinical outcomes were assessed.
RESULTS From September 2012 to January 2015, 250 patients with 335
lesions were enrolled in this study. A total of 445 BVS were placed
with a mean number of implanted scaffolds/ patient of 1.37. Pre-
dilatation was performed in 89.8%. Predilatation balloon: artery ratio
was 1.050.23. Post-dilatation was performed in 54.3%. In 14.5%
baseline imaging using IVUS was used; OCT in 24.9%. Bifurcation was
present in 21.4%, calciﬁcation in 42.2% and total occlusions in 4.2%.
In 38.0% there were AHA classiﬁcation type B2/ C lesions. Mean lesion
length was 22.1013.90 mm. Pre-procedural reference vessel diameter
(RVD) was 2.420.74mm, minimal lumen diameter (MLD)
0.910.45mm and percentage diameter stenosis (%DS) 59.13 0.72.
Post-procedural QCA characteristics were as followed: RVD
2.770.46 mm, MLD 2.300.42 mm and %DS 16.909.04. Median
follow-up period was 559 days (interquartile range [IQR], 371-733
days). Up to 12 months three patients died (all cardiac death) with a
Kaplan Meier estimate of 1.4% at one year. Rate of all myocardial
infarction (MI) was 4.1%, deﬁnite scaffold thrombosis (ST) 1.4%, target
lesion revascularization (TLR) and target vessel revascularization
(TVR) were 3.7%. Non-target vessel revascularization (non-TVR) was
3.8%. Major cardiac adverse events (MACE, a composite endpoint of
cardiac death, TLR and all MI) at one year was 5.5%.
CONCLUSIONS Long-term results in a mixed group of patients imply
that BVS usage is associated with favorable clinical outcomes.
CATEGORIES CORONARY: Bioresorbable Vascular Scaffolds
KEYWORDS Bioabsorbable scaffolds, Coronary artery disease, PCI -
Percutanoeus Coronary Intervention
TCT-528
Bioabsorbable Vascular Scaffold Overexpansion: Insights from in-vitro
post-expansion experiments
Nicolas Foin,1 Renick D. Lee,1 Alessio Mattesini,2 Jing Ni Chan,3
Yingying Huang,4 Gianluca Caiazzo,5 Enrico Fabris,6 Ismail D. Kilic,7
Subbu S. Venkatraman,3 Carlo Di Mario,8 Philip Wong,1 Holger Nef9
1National Heart Centre Singapore, Singapore, Singapore; 2Careggi
Hospital, Florence, Italy; 3Nanyang Technological University,
Singapore, Singapore; 4Nanyang Technological University, Singapore,
CA; 5S. Giuseppe Moscati Hospital, Napoli, Italy; 6BRU, Royal Bromton
NHS Trust, London, United Kingdom; 7Royal Brompton NHS Trust,
London, United Kingdom; 8Imperial College London, London, United
Kingdom; 9Justus-Liebig University of Giessen, Giessen, Germany
BACKGROUND While Bioresorbable Vascular Scaffolds (BVS) are
increasingly used in clinical practice, behavior when post-dilated
beyond their recommended maximum over-expansion diameter re-
mains sparsely documented.
METHODS We examined the post-expansion behavior of the Bio-
resorbable Vascular Scaffold (3.0mm and 3.5mm Absorb BVS; Abbott
Vascular, Santa Clara, CA) after over-expansion with Non-Compliant
(NC) balloons of increasing diameters. After each oversizing step, the
scaffolds were measured and inspected for strut disruption using
